Skip to content

Rybelsus 14 mg tablets

DRUG11 trials

Sponsors

Rigshospitalet, Universitair Medisch Centrum Groningen, Novo Nordisk A/S, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, AstraZeneca AB

Conditions

Chronic Kidney DiseaseCoronary Artery DiseaseCoronary AtherosclerosisCoronary Heart DiseaseDiabetes type 2GlaucomaHyperglycaemia after renal transplantationMild cognitive impairment (MCI) or mild dementia

Phase 2

Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation
WithdrawnCTIS2023-504159-29-00
RigshospitaletHyperglycaemia after renal transplantation
Target: 104Updated: 2023-07-17
Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation
RecruitingCTIS2023-504159-29-01
RigshospitaletHyperglycaemia after renal transplantation
Start: 2024-09-03Target: 104Updated: 2025-11-03
FINESSE; Optimization of albuminuria lowering therapies to individual patients with CKD using FINErenone and SEmaglutide (FINESSE-CKD)
RecruitingCTIS2023-506434-69-00
Universitair Medisch Centrum GroningenChronic Kidney Disease
Start: 2025-02-11Target: 36Updated: 2024-08-28
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax)
RecruitingCTIS2024-513416-98-00
Karolinska University HospitalDiabetes type 2
Start: 2023-01-23Target: 90Updated: 2025-11-25
Effects of GLP-1 analogue in multiple sclerosis
Not yet recruitingCTIS2024-519235-42-00
Comenius University Bratislavain productive age between 18 and 60 years, Patients with confirmed multiple sclerosis (MS), who at the time of investigation are on baseline therapy of the disease for at least 3 months +2
Target: 1Updated: 2024-11-07
A Phase Ilb, Randomized, Double-blind, Placebo ­controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
CompletedCTIS2024-512562-34-00
AstraZeneca ABType 2 Diabetes Mellitus
Start: 2025-02-24End: 2025-12-17Target: 118Updated: 2025-11-19
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus
RecruitingCTIS2024-520322-11-00
F. Hoffmann-La Roche AGType 2 Diabetes Mellitus (T2D)
Start: 2025-09-29Target: 74Updated: 2025-09-08

Phase 3

Phase 4